CGT Commercialisation 2.0: Ranking Markets by Regulatory, Infrastructure & Reimbursement Readiness
Cell and gene therapies are no longer a niche category. With more approvals coming through, payers pushing back harder, and health systems struggling to keep up operationally, CGT commercialisation ha ...
Beyond the Drug: Why Ecosystem Based Commercial Models Are Becoming Critical in Rare Diseases
The quiet truth about rare disease medicines is that a brilliant molecule or a one-time gene therapy is only the opening act. Getting the drug from a lab bench miracle into durable, equitable patient ...
Japan’s Evolving HTA Landscape: What Global Launch Teams Must Know
Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NH ...
The US-UK Drug Pricing Deal: What It Means for Both Countries and the Global Market
For years, the United States and the United Kingdom have stood on opposite ends of the drug pricing spectrum. The US has historically allowed manufacturers to set list prices with relatively few const ...
Mergers & Acquisitions in Pharma — What 2025 taught us and where the momentum is heading in 2026
2025 almost felt like pharma pressed a reset button on dealmaking. Money moved in patches, a handful of blockbuster deals grabbed headlines and reshaped competitive positions, while the broader market ...
Epilansis: A NextGen, Cloud-based Epidemiology Platform for Faster, Smarter Market Decisions
With the healthcare landscape shifting rapidly, teams across biopharma, consulting, med-tech, and healthcare strategy face a common bottleneck: turning scattered epidemiology data, literature, real wo ...
Eight Emerging U.S. Medical Cost & Access Drivers to Watch in 2026
The U.S. healthcare system never really sits still but 2026 is shaping up to be a year where cost, access, and innovation intersect in new and sometimes uncomfortable ways. From the Inflation Reductio ...
The Forgotten Power of the TPP: Why Many Biopharma Projects Fail Without It
In the fast‐moving world of biopharma innovation, it’s easy to get excited by the science – the novel target, the breakthrough molecule, the cutting-edge modality. But amid that excitement, one strate ...
EU Pharmaceutical Supply Chain: How to Shrink Upstream Risk Without Shrinking Access
Europe’s pharmaceutical landscape is undergoing a significant change due to its medicine shortage problem, which has a stubborn root cause: fragile upstream links. The situation becomes apparent at th ...
Pharma Licensing 2025 and Beyond: Rethinking Strategic Partnerships for Long-Term Value
Introduction: Licensing as a Growth Engine in Pharma The global pharmaceutical and biotech companies are entering an era of collaboration, agility, and strategic alliances. As the R&D cost rises ...